title: Anti-VEGF with 3-week intervals is effective on anemia in a patient with severe hereditary hemorrhagic telangiectasia.
authors.forename: Philip
authors.initials: P
authors.lastname: Fodstad
authors.forename: Sinan
authors.initials: S
authors.lastname: Dheyauldeen
authors.forename: Marit
authors.initials: M
authors.lastname: Rinde
authors.forename: Gregor
authors.initials: G
authors.lastname: Bachmann-Harildstad
mesh_terms: D000328:Adult; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D004334:Drug Administration Schedule; D004844:Epistaxis / Q000209:etiology; D006397:Hematinics / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D012720:Severity of Illness Index; D013683:Telangiectasia, Hereditary Hemorrhagic / Q000503:physiopathology; D016896:Treatment Outcome; D042442:Vascular Endothelial Growth Factors / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D006397:Hematinics; D042442:Vascular Endothelial Growth Factors; D000068258:Bevacizumab
references.citation: Laryngoscope. 2004 Apr;114(4):705-9
references.pmid: 15064628
references.citation: N Engl J Med. 2009 May 14;360(20):2143-4
references.pmid: 19439755
references.citation: Laryngoscope. 2009 Feb;119(2):284-8
references.pmid: 19160429
references.citation: Am J Rhinol. 2006 Jan-Feb;20(1):87-90
references.pmid: 16539301
references.citation: Liver Transpl. 2008 Feb;14(2):210-3
references.pmid: 18236396
references.citation: Ann Hematol. 2006 Sep;85(9):631-2
references.pmid: 16807748